Secondary Logo

Journal Logo

Effects of sevoflurane on primary neuronal cultures of embryonic rats

Berns, Monikaa,1; Zacharias, Robertb,1; Seeberg, Lucasb; Schmidt, Marenb; Kerner, Thoralfb

European Journal of Anaesthesiology (EJA): July 2009 - Volume 26 - Issue 7 - p 597–602
doi: 10.1097/EJA.0b013e32832a0c61
Original Articles – Neuro and Monitoring
Free

Background and objective Commonly used anaesthetics can cause neurodegeneration in the developing brain. Sevoflurane, a widely used substance in paediatric anaesthesia, has not been analysed thus far. This study was carried out to investigate the effects of sevoflurane on neuronal cell viability.

Methods Primary cortical neuronal cultures were prepared from Wistar rat embryos (E18), kept in 100 μl Gibco–Neurobasal-A medium and exposed to 4 and 8 Vol.% sevoflurane for up to 48 h. Cell viability was assessed using the methyltetrazolium assay and was related to untreated controls. To evaluate the role of γ-aminobutyric acid type A receptors, untreated cells were preincubated with the receptor antagonists gabazine or picrotoxin and were subsequently exposed to 8 Vol.% sevoflurane and the receptor antagonist. Cell viability was assessed and compared with that of sevoflurane-treated controls.

Results Up to 6 (8 Vol.%) and 12 h (4 Vol.%) of exposure to sevoflurane, cell viability was equal when compared with untreated controls. Only longer exposure times led to significantly lowered cell viability. After 12 h of exposure, no significant differences in cell viability were found between these two series. Cell viability of cultures treated with sevoflurane and the receptor antagonists showed no significant differences when compared with sevoflurane-exposed controls.

Conclusion These results suggest that sevoflurane does not cause neurodegeneration in primary cortical neurons of the rat following clinically relevant exposure times and concentrations.

aKlinik für Neonatologie, Campus Virchow-Klinikum, Charité Centrum 17 für Frauen-, Kinder- und Jugendmedizin mit Perinatalzentrum und Humangenetik, Germany

bKlinik für Anästhesiologie und operative Intensivmedizin, Campus Virchow-Klinikum und Charité Campus Mitte, Charité Centrum 7 für Anästhesiologie, OP-Management und Intensivmedizin Charité Centrum 7, Berlin, Germany

1M. Berns and R. Zacharias contributed equally to the present study.

Received 15 July, 2008

Revised 27 November, 2008

Accepted 23 January, 2009

Correspondence to Dr Monika Berns, Charité - Campus Virchow-Klinikum, Klinik für Neonatologie, Augustenburger Platz 1, 13353 - Berlin, Germany Tel: +49 30 450 666598; fax: +49 30 450 566922; e-mail: monika.berns@charite.de

Back to Top | Article Outline

Introduction

During a certain phase in brain development, called the brain growth spurt, neurons seem to be particularly susceptible to neurodegenerative influences. In humans, this sensitive period ranges from the third trimester of pregnancy to the age of about 2 years. The rodent brain goes through a comparable developmental period in the first 3 weeks after birth [1–3]. Anaesthetics have a major influence on brain physiology. Neuroprotective influences on the adult brain have been demonstrated for anaesthetic agents such as propofol, barbiturates and volatile anaesthetics [4]. Interestingly, Ikonomidou et al. [3] reported in 2000 that N-methyl-D-aspartate (NMDA)-glutamate-receptor antagonists and γ-aminobutyric acid type A-receptor agonists (GABAA-RA) can induce neurodegeneration in the embryonic brain. Until now, the neurodegenerative effects of various anaesthetic agents and sedatives such as ketamine, propofol, midazolam, isoflurane and nitrous oxide have been shown in the neonatal rodent brain [5,6]. For those anaesthetics, as well as for sevoflurane, a mechanism of action via GABAA agonism or glutamate antagonism or both is known [5,7,8].

Premature infants, newborns and pregnant women may undergo anaesthesia and sedation during various diagnostic and surgical procedures. Some anaesthetics used in paediatric anaesthesia have not yet been examined concerning their neurodegenerative effects. Sevoflurane is the main induction agent in paediatric anaesthesia and a widely used substance for the maintenance of general anaesthesia. For mask induction, it displays favourable properties such as a sweet smell and fast onset and offset [9]. Despite its widespread use in paediatric anaesthesia, sevoflurane has not yet been analysed with regard to possible neurodegenerative effects on developing neurons. Therefore, this study was designed to investigate the time and concentration dependence of its effects on primary neuronal cultures of the rat.

Back to Top | Article Outline

Methods

Primary cortical neuronal culture

Primary neuronal cultures were prepared as described elsewhere [10]. Briefly, Wistar rat embryos (E16-E18) (Forschungseinrichtung für Experimentelle Medizin, Charité-Universitätsmedizin Berlin, Germany) were used for cell culture preparation [10,11]. All procedures were performed according to the local guidelines for animal research approved by the Charité-Universitätsmedizin Berlin. Cerebral cortices were dissected in serum-free neurobasal medium with B27 supplement (Gibco, Invitrogen GmbH, Karlsruhe, Germany) and the meninges were removed. After mild trypsinization [15 min at 37°C in trypsin/ethylenediaminetetraacetic acid (0.05/0.02%)] in phosphate-buffered saline (PBS), the fragments were rinsed twice with PBS and once with dissociation medium (neurobasal medium with 2% B27 supplement, 1% penicillin and streptomycin and 1% L-glutamine) and subjected to mechanical dissociation by repeated aspirations through a Pasteur pipette in dissociation medium. Cell suspension was pelleted by mild centrifugation (1200 U min−1, 2 min at room temperature) and seeded in flat-bottom wells in neurobasal medium with B27 supplement containing 2 mmol l−1 L-glutamine, at a density of 3 × 106 ml−1. Prior to cell plating, wells were treated with poly-D-lysine (0.5% w/v in water; Sigma, St Louis, Missouri, USA) for 1 h at room temperature and rinsed twice with water. Cells were kept in a fully humidified incubator at 37°C under 5% CO2. After 4 days in vitro (DIV), 50% of the medium was removed and replaced with fresh medium. Cultures obtained under these conditions appeared to contain mostly neuronal cells (99%) determined by indirect immunocytochemistry for neurofilament.

Back to Top | Article Outline

Cell treatment with sevoflurane

After a total of 14–16 DIV, cells were exposed in two series to either 4 or 8 Vol.% sevoflurane (Abbott, Wiesbaden, Germany) via a vaporizer (Sevorane, Draeger-Vapor 2000, Draeger, Germany) for 3, 6, 9, 12, 24 and 48 h. Control cells remained untreated and measurements were taken at the same time points as the sevoflurane-treated cells.

Therefore, cell cultures were placed in the incubation chamber (Billups-Rothenburg, Del Mar, California, USA) and were then perfused with fresh air (21% O2, 5% CO2 and 69% N2) containing 4 or 8 Vol.% sevoflurane [12,13] After 10 min with a flow rate of 6 l min−1, the resultant atmosphere of the chamber reached a steady state level of 4 or 8 Vol.% sevoflurane measured by a Capnomac gas monitor (Datex-Ohmeda, Helsinki, Finland). The sevoflurane concentration did not change within the incubation time of 24 or 48 h. Control cells were superfused for the same length of time with fresh air only. Subsequently, the chambers were sealed and placed in the same incubator.

In order to explore the influence of GABAA receptors, untreated cell plates were preincubated with the GABAA receptor antagonists gabazine (0.1 mmol l−1) or picrotoxin (0.1 mmol l−1) for 30 min. After preincubation, these cultures were exposed to 8 Vol.% sevoflurane in the presence of the antagonists. Cell viability tests were also performed and assessed after 3, 6, 9, 12, 24 and 48 h of incubation and were compared with the controls, which were exposed to sevoflurane only.

To evaluate the mechanisms by which sevoflurane affects neuronal cells, cultures were additionally treated with the pan-caspase inhibitor zVAD-fmk [0.04 mmol l−1; Promega, Mannheim, Germany] and inhibitors of extracellular signal-regulated kinase [0.01 mmol l−1; (ERK1/2)-U0126, Cell Signaling Technology, Danvers, Massachusetts, USA] or phosphatidylinositol-3-kinase [0.01 mmol l−1; (PI3K)-ly294002, Cell Signaling Technology] in combination with sevoflurane 8 Vol.%.

Back to Top | Article Outline

Cell viability assay

The methyltetrazolium (MTT) assay is based on the reduction of the tetrazolium salt (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoliumbromide) (Sigma) to coloured formazan by active dehydrogenases within live mitochondria to determine cell viability [14]. Neuronal cells were plated onto 96-well plates coated with poly-D-lysine (Sigma) in 100 μl aliquots (60 000 cells per well) and treated with sevoflurane as described. Control cells were kept in neurobasal medium. After 3, 6, 9, 12, 24 and 48 h, 10 μl MTT at a final concentration of 0.5 mg ml−1 was added for 2 h. Insoluble purple formazan grains were solubilized by adding 100 μl of 10% sodium dodecyl sulphate – 0.01 N HCl. Absorbance at 570 nmol l−1 and a reference wavelength of 630 nm were analysed using a microplate reader (BioRad, Munich, Germany).

Back to Top | Article Outline

Apoptosis and necrosis detection ELISA

To quantify apoptosis and necrosis, histone-complexed DNA fragments, from the cytoplasm of apoptotic cells or when released from necrotic cells, were detected immunochemically and the amount was determined by spectrophotometry. After incubation of cells with sevoflurane as described, 20 μl of cell-incubating medium containing DNA from necrotic cells that leaked through the membrane during incubation was transferred to a streptavidin-coated well. The remaining medium was discarded. To determine the amount of apoptotic nucleosomes, apoptotic cells were lysed, centrifuged and an aliquot of the supernatant was likewise transferred to a streptavidin-coated well. The oligosomal DNA was quantitated using Cell Death Detection ELISAPlus (Roche Diagnostics, Mannheim, Germany, Cat No. 11 920685 001), according to the manufacturer's protocol. Results are expressed as absorbance from the supernatant of the lysate as well as from the incubating medium of the sevoflurane-treated cells against the values of untreated cells as controls.

Back to Top | Article Outline

Light phase contrast photomicrographs

To visualize the cell damage caused by sevoflurane (8 Vol.%), we took representative photomicrographs of exposed cultures and control cultures with an Olympus digital camera (Olympus, Hamburg, Germany).

Back to Top | Article Outline

Statistical analysis

Statistical significance was evaluated with the one-way analysis of variance (ANOVA) and with Bonferroni's multiple comparison test. The software used was GraphPad prism 4.03 (GraphPad software, Inc., San Diego, California, USA). Statistical significance was defined as a P value less than 0.05.

Back to Top | Article Outline

Results

Cell viability for different sevoflurane concentrations

To determine the influence of sevoflurane alone in different concentrations on neuronal survival, the cell viability was evaluated. After incubation of the cultured cells with 4 and 8 Vol.% sevoflurane for 3, 6, 9, 12, 24 and 48 h, cell viability was measured by using MTT reduction (Fig. 1). The test series with 4 Vol.% sevoflurane showed no significantly reduced cell viability until 12 h of exposure. After 24 h, cell viability was reduced significantly (48.6 ± 9.9%, P < 0.001) compared with the untreated control group. The cell cultures treated with 8 Vol.% sevoflurane displayed no significant decrease in cell viability in the first 6 h. In these test series, cell viability was reduced significantly after 9 h (66.4 ± 10.9%, P < 0.01). Prolonged exposure of cultures to sevoflurane led to a more pronounced cell death in both groups. Until 9 h of exposure to sevoflurane, cell viability values were significantly lower in cultures treated with 8 Vol.% sevoflurane compared with cells with the same duration of exposure incubated with 4 Vol.%. From 12 h of exposure, no significant differences could be shown between both groups (Fig. 1).

Fig. 1

Fig. 1

Light phase contrast photographs taken to illustrate the microscopic differences showed a marked effect on cells after incubation with 8 Vol.% sevoflurane for 24 h (Fig. 2).

Fig. 2

Fig. 2

Back to Top | Article Outline

Cell viability for sevoflurane with GABAA-receptor antagonists

After 3, 6, 9, 12, 24 and 48 h, no significant differences in cell viability of cells treated with 8 Vol.% sevoflurane and the GABAA-receptor antagonists gabazine or picrotoxin compared with control cells (sevoflurane, 8 Vol.%) could be demonstrated (Fig. 3).

Fig. 3

Fig. 3

Back to Top | Article Outline

Evaluation of type of cell death

To further specify the type of cell death, we analysed the cell viability values after coincubation of cell cultures for 24 h with 8 Vol.% sevoflurane and inhibitors of the apoptotic pathway (Fig. 4). Incubating the cells with zVAD-fmk (pan-caspase inhibitor) did not significantly increase the number of surviving cells. ERK1/2 and PI3K are mediators of the antiapoptotic pathway. To evaluate their influence on the antiapoptotic pathway, cells were exposed to U0126 (inhibitor of ERK1/2) and ly294002 (inhibitor of PI3K). This experiment did not show any additional loss in cell viability. Furthermore, evaluation of the type of cell death by using Cell Death Detection ELISA revealed no statistically significant differences.

Fig. 4

Fig. 4

Back to Top | Article Outline

Discussion

The present study was performed to investigate time-dependent and concentration-dependent effects of sevoflurane on developing neurons. We, therefore, used primary neuronal cultures of embryonic rats. Furthermore, the involvement of its main mechanism of action on the described effects should be examined. The main finding of the present study is that sevoflurane has no effect on neuronal cell viability in clinically relevant concentrations and exposure times. Neuronal damage was only observed after exposure times and concentrations that are relatively high in comparison with its use in clinical practice. GABAA-receptor antagonists did not abrogate sevoflurane-induced cell damage.

Neurodegenerative influences of anaesthetic agents for the developing brain are the focus of various publications. Most studies published in this field presented data on the neurodegenerative effects of ketamine, an NMDA-receptor-blocking anaesthetic agent that is not often used any more in paediatric anaesthesia [5]. Extended neurodegeneration after application of ketamine and other NMDA-receptor antagonists was shown in the brain of neonatal rats [15] and mice [16]. A recent study performed by Fredriksson et al.[2] interestingly shows that the coadministration of GABAergic substances like barbiturates and propofol potentiates neonatal brain cell death caused by ketamine. Furthermore, ketamine at nonapoptotic concentrations can impair dendritic arbor development of GABAergic neurons as shown for cultured rat neurons [17]. Another substance that acts mainly via the inhibition of the NMDA receptors, nitrous oxide [18], showed the induction of behavioural changes as well as neurodegenerative effects in different in-vivo settings [19,20].

Neurodegenerative effects have also been demonstrated for substances with predominantly GABAA-agonistic mechanisms of action. The studies performed on neonatal mice [2,16,21] showed neurodegeneration following application of benzodiazepines, propofol and barbiturates. Additionally, those studies [2,16,21] showed much more intense neurodegeneration triggered by combinations of anaesthetics such as thiopental and propofol, ketamine and propofol, midazolam and ketamine, or diazepam and phenobarbital. In contrast to glial cells, GABAergic neurons displayed vulnerability to propofol administration in rat glial-cell and neuronal-cell cocultures [22]. Additional data obtained from cell culture experiments showed that propofol in concentrations not sufficient to induce cell death could, in contrast to midazolam, alter dendritic differentiation [23].

Our data extend findings made for the volatile anaesthetic isoflurane [12,24]. Wise-Faberowski et al. [12] observed neurodegenerative effects in organotypic hippocampal slice cultures after only 5 h of exposure to 1.5 Vol.% isoflurane and Jevtovic-Tedrodovic et al. [24] analysed the effects of isoflurane alone or in combination with midazolam and nitrous oxide after just 6 h in an in-vivo model of 7-day-old rats. We were able to demonstrate neurodegeneration for the volatile anaesthetic sevoflurane, particularly used in paediatric anaesthesia. Our data indicate a clear concentration and time dependence of the onset of significant neurotoxic effects. Namely, exposure to clinically relevant concentrations of sevoflurane (4 Vol.%) induced significant neurodegeneration only after 24 h. Using high concentrations (8 Vol.%), we could determine the onset of neurodegenerative effects after just 9 h.

The concentration of 8 Vol.% sevoflurane exceeds commonly used minimal alveolar concentrations (MACs) of ca. 3.3 Vol.% in human neonates [25,26] and of 3.74 Vol.% in 9-day-old rats [27]. Even though concentrations of up to 8 Vol.% are used in the inspiratory line of the respirator [28], these concentrations are only applied for a matter of minutes during the induction of anaesthesia and are not measured in the expiratory line after reaching a steady state. When using the 4 Vol.% concentration, which is close to clinically relevant concentrations, we were able to determine a significant decrease in cell viability only after 24 h of exposure. Thus, sevoflurane displays no neurodegenerative effects in the model used when applied in concentrations and exposure times relevant in paediatric anaesthesia. As ours is an in-vitro model, we could not exclude the possibility that irreversible neuronal damage could occur in vivo at sevoflurane concentrations and exposure times much lower than those that cause cell death in vitro. In additional experiments, we evaluated cell viability following a 3 h-long sevoflurane exposure and 21 h washout (data not shown). Cell viability was reduced at a concentration of 8 Vol.% but not at 4 Vol.%. This model – widely used in studies for detecting neuroprotection after isoflurane preconditioning followed by ischaemia in brain slice cultures [13,29] – could be the basis for further investigations before stating that sevoflurane does not affect neuronal viability or whether sevoflurane could induce delayed apoptotic response. In-vivo studies [3,30] found that there is a time window from embryonic day 19 to postnatal day 14 when developing neurons are particularly sensitive to anaesthetics. Within this period, the brain of postnatal day 7 rats is thought to be particularly sensitive to neurotoxic effects [24]. Neuronal maturation in primary cultures was initiated between 7 and 11 DIV [31]. We used mature cultures at 14–16 DIV for our experiments. Considering that immature neuronal cultures are more sensitive, corresponding experiments should be done with immature cultures 5 DIV.

As we know, the GABAA receptor is the main receptor on which sevoflurane and other volatile anaesthetics act [7,8]. Hyperpolarization of immature neurons by GABA agonists may be a possible mechanism of the dose-dependent and time-dependent toxicity of sevoflurane [32]. Even though sevoflurane enhances inhibitory postsynaptic channel activity at the GABAA receptors, picrotoxine and gabazine, as GABAA-receptor antagonists [33], could not reduce neuronal damage.

In diverse models of neurodegeneration by anaesthetic substances, apoptosis was defined as the underlying mechanism for injury. Exposure to ketamine, midazolam or a combination of these drugs triggered apoptotic neurodegeneration in the developing mouse brain [16]. Apoptosis measured with Fluoro-Jade staining was increased in brains of mice treated with ketamine and propofol or ketamine and thiopental or a high dose of propofol alone [2]. In our study, sevoflurane showed neuronal damage predominantly via necrosis. Inhibition of the extrinsic pathway of apoptosis, via activation of caspase-3 with zVAD-fmk, could not avoid the degeneration of sevoflurane-treated cells [34]. On the other hand, we know that there is an intrinsic pathway in apoptosis. Inhibition of this pathway mediated by ERK1/2 and PI3K increased apoptosis in a model of hypoxia-induced apoptosis in neonatal brain slices [35]. In cultures of immature oligodendrocytes hyperoxia induced apoptosis and reduced levels of phosphorylated ERK1/2 and PI3K. Oestrogen antagonized this effect and significantly reduced apoptosis [36]. Activation of PI3K or ERK1/2 protects against apoptosis [37,38]. In our experiments, inhibition of the antiapoptotic pathway showed no additional sensitivity to apoptosis. Even though the intrinsic and extrinsic apoptotic pathways were not activated in our model, it has been reported that both pathways are activated in vivo by isoflurane in neonatal rats [39]. Other investigators used detection of caspase-3 activation, either by western blot or by immunohistochemistry, to determine apoptotic cell death in the neonatal brain [40,41].

Even though this study is limited as an in-vitro model with neuronal cells, we demonstrated for the first time that, at concentrations and exposure times relevant for clinical anaesthesia, sevoflurane displays no neurodegenerative effects. This indicates the possibility of developing in-vivo models to describe time slots for safe anaesthesia with concentrations as low as possible, while still capable of maintaining a sufficient anaesthetic plane. Further studies should be done to investigate delayed effects of sevoflurane and to identify the underlying mechanisms of neuronal damage during sevoflurane anaesthesia. Direct in-vitro comparison studies would be important in establishing a difference between volatile anaesthetics. In addition, future clinical studies will be necessary to develop safe anaesthetic protocols.

Back to Top | Article Outline

Acknowledgements

The present work was supported by internal university research grants of the Charité-Universitätsmedizin Berlin. We thank Anne Carney for editorial assistance.

Back to Top | Article Outline

References

1 Dobbing J, Sands J. Comparative aspects of the brain growth spurt. Early Hum Dev 1979; 3:79–83.
2 Fredriksson A, Ponten E, Gordh T, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthesiology 2007; 107:427–436.
3 Ikonomidou C, Bittigau P, Ishimaru MJ, et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000; 287:1056–1060.
4 Head BP, Patel P. Anesthetics and brain protection. Curr Opin Anaesthesiol 2007; 20:395–399.
5 Mellon RD, Simone AF, Rappaport BA. Use of anesthetic agents in neonates and young children. Anesth Analg 2007; 104:509–520.
6 Gascon E, Klauser P, Kiss JZ, Vutskits L. Potentially toxic effects of anaesthetics on the developing central nervous system. Eur J Anaesthesiol 2007; 24:213–224.
7 Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348:2110–2124.
8 Rudolph U, Antkowiak B. Molecular and neuronal substrates for general anaesthetics. Nat Rev Neurosci 2004; 5:709–720.
9 Lerman J. Inhalational anesthetics. Paediatr Anaesth 2004; 14:380–383.
10 Brewer GJ. Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 1995; 42:674–683.
11 Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22:10291–10301.
12 Wise-Faberowski L, Zhang H, Ing R, et al. Isoflurane-induced neuronal degeneration: an evaluation in organotypic hippocampal slice cultures. Anesth Analg 2005; 101:651–657.
13 Sullivan BL, Leu D, Taylor DM, et al. Isoflurane prevents delayed cell death in an organotypic slice culture model of cerebral ischemia. Anesthesiology 2002; 96:189–195.
14 Buhrer C, Atzpodien J, Oz S, Henze G. Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro. Pediatr Hematol Oncol 1991; 8:243–249.
15 Ikonomidou C, Bosch F, Miksa M, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999; 283:70–74.
16 Young C, Jevtovic-Todorovic V, Qin YQ, et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br J Pharmacol 2005; 146:189–197.
17 Vutskits L, Gascon E, Tassonyi E, Kiss JZ. Effect of ketamine on dendritic arbor development and survival of immature GABAergic neurons in vitro. Toxicol Sci 2006; 91:540–549.
18 Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4:460–463.
19 Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br J Pharmacol 2000; 130:1692–1698.
20 Mullenix PJ, Moore PA, Tassinari MS. Behavioral toxicity of nitrous oxide in rats following prenatal exposure. Toxicol Ind Health 1986; 2:273–287.
21 Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A 2002; 99:15089–15094.
22 Honegger P, Matthieu JM. Selective toxicity of the general anesthetic propofol for GABAergic neurons in rat brain cell cultures. J Neurosci Res 1996; 45:631–636.
23 Vutskits L, Gascon E, Tassonyi E, Kiss JZ. Clinically relevant concentrations of propofol but not midazolam alter in vitro dendritic development of isolated gamma-aminobutyric acid-positive interneurons. Anesthesiology 2005; 102:970–976.
24 Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003; 23:876–882.
25 Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999; 36:13–26.
26 Hobbhahn J, Funk W. Sevoflurane in pediatric anesthesia. Anaesthesist 1996; 45(Suppl 1):S22–S27.
27 Orliaguet G, Vivien B, Langeron O, et al. Minimum alveolar concentration of volatile anesthetics in rats during postnatal maturation. Anesthesiology 2001; 95:734–739.
28 Ho KY, Chua WL, Lim SS, Ng AS. A comparison between single- and double-breath vital capacity inhalation induction with 8% sevoflurane in children. Paediatr Anaesth 2004; 14:457–461.
29 Lee JJ, Li L, Jung HH, Zuo Z. Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology 2008; 108:1055–1062.
30 Ikonomidou C, Bittigau P, Koch C, et al. Neurotransmitters and apoptosis in the developing brain. Biochem Pharmacol 2001; 62:401–405.
31 Katayama M, Mizuta I, Sakoyama Y, et al. Differential expression of neuroD in primary cultures of cerebral cortical neurons. Exp Cell Res 1997; 236:412–417.
32 Rheims S, Minlebaev M, Ivanov A, et al. Excitatory GABA in rodent developing neocortex in vitro. J Neurophysiol 2008; 100:609–619.
33 Johnston GA. GABAA receptor pharmacology. Pharmacol Ther 1996; 69:173–198.
34 Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115:2665–2672.
35 Hirai K, Hayashi T, Chan PH, et al. PI3K inhibition in neonatal rat brain slices during and after hypoxia reduces phospho-Akt and increases cytosolic cytochrome c and apoptosis. Brain Res Mol Brain Res 2004; 124:51–61.
36 Gerstner B, Sifringer M, Dzietko M, et al. Estradiol attenuates hyperoxia-induced cell death in the developing white matter. Ann Neurol 2007; 61:562–573.
37 Buckley S, Driscoll B, Barsky L, et al. ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Am J Physiol 1999; 277:L159–L166.
38 Honda K, Sawada H, Kihara T, et al. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J Neurosci Res 2000; 60:321–327.
39 Yon JH, Daniel-Johnson J, Carter LB, Jevtovic-Todorovic V. Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. Neuroscience 2005; 135:815–827.
40 Ma D, Williamson P, Januszewski A, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology 2007; 106:746–753.
41 Olney JW, Tenkova T, Dikranian K, et al. Ethanol-induced caspase-3 activation in the in vivo developing mouse brain. Neurobiol Dis 2002; 9:205–219.
Keywords:

anaesthesia general; apoptosis; embryonic culture; necrosis; neurons; sevoflurane

© 2009 European Society of Anaesthesiology